Lack Of Competition Increases Generic Drug Prices

Researchers say that market competition levels strongly depend on generic drug price, as more than four in five prescriptions filled are for generic drugs.

Has the cost of the generic drugs increased? It could be due to a lack of competition among drug manufacturers, reveals a new study from University of Florida College of Pharmacy. //

. More than four in five prescriptions filled in the U.S. are for generic drugs, and UF researchers have found that market competition levels are strongly associated with generic drug price increase. Market competition levels are defined by the number of manufacturers producing a generic drug.

European Union Suspends the Sale of 700 Generic Drugs Made in India
There is no evidence of harm or lack of effectiveness in the medicines. They were taken off to ensure patient safety and to retain confidence in EU system.

‘In order to keep the generic drugs affordable for consumers, it is necessary to identify factors which influence a change in the prices of the drugs.’

"The U.S. health care system has recently witnessed a relatively new phenomenon where prices for some older generic drugs have increased hundreds -- even thousands of percentage points in a short time span," said Chintan Dave, Pharm.D., the lead author of the study and a graduate student in the UF College of Pharmacy's department of pharmaceutical outcomes and policy.

"There is a lot of speculation that these increases are due to drug shortages or industry consolidation, but without looking through a lens of scientific rigor, you cannot make these assumptions.

"This is one of the first studies that has linked market competition levels to generic drug prices for a large cohort of generic drugs," he said.

Variation in Appearance of Generic Drugs may Disrupt Use
Generic versions of the same prescription drug are clinically interchangeable but depending on the manufacturer, they often look different.

In the study, published in the Annals of Internal Medicine, UF researchers analyzed 1.08 billion prescription drug claims from 2008-13 and examined 1,120 generic drugs. Using the Herfindahl-Hirschman Index, or HHI, a commonly accepted measure of market competition, researchers estimated competition levels for each drug. HHI values were calculated using a formula that takes into account a manufacturer's market share.

Nearly half the generic drugs studied were found to have competition levels resembling a duopoly, a competition level where only two manufacturers produce a drug.

Suppression of Generic Drugs Becoming A Health Threat in the United States
The market price of pharmaceuticals is costing patients more than $100,000 per year, leading to an increase in public health spending.

After controlling for other factors, a generic drug in the highest marketing competition group was expected to see a decrease of 32 percent in price over the study period, while a generic drug in the lowest market competition was expected to see a price increase of 47 percent over the same period.

In addition, researchers found low market competition levels have a more pronounced correlation with drug prices in lower-priced generic drugs compared with their higher-priced counterparts.

Indian Generic Drug Market May Grow Fivefold In 10 To 15 Years
India is now trying to focus on drug development and discovery for urban diseases and diseases that do not have a proper treatment protocol.

UF researchers acknowledge the study period's conclusion in 2013 is a limitation of the research. Several widely publicized cases of generic drug increases have occurred in recent years. In addition, generic drugs that entered the market after 2008 were not included in the study.

"The connection this study establishes between market competition levels and generic drug prices should be an eye-opener for regulators responsible for the generic drug market," Dave said.

"In recent years, some generic manufacturers have sought to consolidate their market power by merging with rivals, but these mergers risk decreasing competition levels in parts of an already uncompetitive U.S. generic drug market."

While rapidly increasing generic drug prices should attract other manufacturers to the market, this does not always happen due to several potential deterrents. The study points to the three-year review time for new generic drug applications at the Food and Drug Administration's Office of Generic Drugs as one of the outside factors underlying generic drug price increases.

Without new policies to stabilize generic drug markets in response to a decrease in competition, Dave said consumers may continue to see prices soar for some generic medications.

"Everyone assumes generic drugs are going to be inexpensive, but this may no longer be the case," Dave said. "If you go to a pharmacy and find that your generic medication is no longer affordable, market competition levels may have played a role in the price increase.

"This study is vitally important in identifying factors that influence a change in drug price, in order to keep generic drugs affordable for consumers," he said.

Source-Eurekalert